Baldwin Wealth Partners LLC MA boosted its holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) by 104.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 355,961 shares of the company's stock after purchasing an additional 181,831 shares during the quarter. Baldwin Wealth Partners LLC MA owned approximately 1.84% of Nuvectis Pharma worth $1,926,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in NVCT. Geode Capital Management LLC boosted its position in shares of Nuvectis Pharma by 49.8% during the 3rd quarter. Geode Capital Management LLC now owns 79,716 shares of the company's stock valued at $501,000 after acquiring an additional 26,489 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Nuvectis Pharma by 20.7% in the 2nd quarter. Renaissance Technologies LLC now owns 74,500 shares of the company's stock worth $472,000 after buying an additional 12,800 shares in the last quarter. Nations Financial Group Inc. IA ADV purchased a new position in shares of Nuvectis Pharma in the 3rd quarter worth $63,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Nuvectis Pharma in the 2nd quarter worth about $58,000. Finally, GSA Capital Partners LLP raised its position in shares of Nuvectis Pharma by 3.7% during the 3rd quarter. GSA Capital Partners LLP now owns 50,129 shares of the company's stock valued at $315,000 after buying an additional 1,790 shares in the last quarter. 96.77% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, CEO Ron Bentsur bought 20,000 shares of the stock in a transaction on Friday, November 15th. The stock was bought at an average price of $4.92 per share, for a total transaction of $98,400.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,266,424 shares in the company, valued at approximately $16,070,806.08. This represents a 0.62 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Marlio Charles Mosseri purchased 17,000 shares of the business's stock in a transaction dated Friday, December 13th. The stock was bought at an average price of $4.70 per share, for a total transaction of $79,900.00. Following the completion of the acquisition, the insider now directly owns 2,612,000 shares in the company, valued at approximately $12,276,400. This trade represents a 0.66 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 43,500 shares of company stock valued at $209,205 over the last quarter. 35.78% of the stock is owned by corporate insiders.
Nuvectis Pharma Stock Performance
NVCT stock traded up $0.18 during mid-day trading on Monday, reaching $6.73. 67,442 shares of the stock traded hands, compared to its average volume of 106,459. The business has a 50-day moving average price of $5.26 and a two-hundred day moving average price of $6.34. The stock has a market capitalization of $130.03 million, a PE ratio of -5.80 and a beta of 0.17. Nuvectis Pharma, Inc. has a one year low of $4.44 and a one year high of $12.10.
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01. During the same period in the previous year, the firm posted ($0.37) EPS. On average, equities analysts expect that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.
About Nuvectis Pharma
(
Free Report)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Featured Stories
Before you consider Nuvectis Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.
While Nuvectis Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
